Scale, scope and spillovers : the determinants of research productivity in ethical drug discovery by Henderson, Rebecca. & Cockburn, Iain.
Scale, Scope and Spillovers:
The Determinants of Research Productivity
in Ethical Drug Discovery
Rebecca Henderson, M.I.T. & NBER
&
Iain Cockburn, U.B.C.& NBER
WP # 3629-93 August 1993
This research was funded by four pharmaceutical companies and by the Sloan Foundation. Their
support is gratefully acknowledged. We would also like to express our appreciation to all of those firms
that contributed data to the study, to Richard Caves and Zvi Griliches, and to seminar participants at the
NBER, UBC, MIT, Stanford, Northwestern, Columbia and Carnegie Mellon, for their helpful comments
and suggestions. The conclusions and opinions expressed in this paper are our own, and any errors or
omissions remain entirely our responsibility.
I I
Abstract
This paper presents the results of a study of the determinants of research productivity
in the pharmaceutical industry. Using disaggregated, internalfirm data at the
research program level from ten major pharmaceutical companies, we find no
evidence of increasing returns to scale at either the firm or the research program
level. However our results suggest that there are three benefits to running research
programs within the context of larger and more diversified R&D efforts: economies of
scale arising from sharing fixed costs; economies of scope arising from the opportunity
to exploit knowledge across program boundaries within the firm; and the enhanced
ability to absorb internal and external spillovers. We alsofind that spillovers between
firms may play a major role in increasing research productivity. The paper also
speaks directly to the question offirm heterogeneity. A significant proportion of the
'firm effect" identified in previous studies can be explained by the slowly changing
composition of the research portfolio, as well as by less easily measured aspects of
innovative capability.
Introduction
While there is considerable agreement that economies of scale and scope in performing R&D
and the magnitude of R&D spillovers may have important implications for research productivity,
research to date has been far from conclusive. The theoretical literature is divided, for example, as to
the effects that relative firm size or the presence of spillovers should have on incentives to undertake
research (Dasgupta and Stiglitz (1980); Spence, (1984)), while empirical work has generated
surprisingly inconclusive and sometimes contradictory results. (Cohen and Levin, (1989).) Several
observers have suggested that this is the result of a historical reliance upon aggregated data, combined
with a failure to control adequately for firm or industry effects (Baldwin and Scott, (1987); Cohen
and Levin, (1989)). In this paper we look inside the firm for evidence on the importance of scale,
scope and spillovers for research productivity, using detailed, disaggregated, data at the level of the
research program obtained from the internal records of ten major research-oriented pharmaceutical
companies.
The enriched understanding of the production technology of innovation which this research
provides may help to resolve several debates in the economics of industrial organization. There are
also implications for the theory of the firm. For example several scholars, notably Chandler (1990),
have suggested that the presence of very large firms in modern capitalist economies is driven by the
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opportunity to exploit internal economies of scale and scope. Moreover since the size of research
programs, firm size and spillover regimes may be dramatically affected by regulatory policy, a better
understanding of their effects upon research productivity can help to lay the ground work for
informed public policy.
Data from the pharmaceutical industry are particularly well suited to studying these issues.
The industry is extremely research intensive, and successful research drives firm performance. As a
result nearly every firm in the industry conducts multiple research programs that compete directly
with each other, offering us a rich data set. Research effort is relatively homogeneous, so that a
comparison of research programs across firms is not confounded by unobservable variation in
technology. Moreover the nature of the technology is such that it is possible to construct reasonable
measures of technological "distance" in order to evaluate the effects of spillovers. A study of research
productivity in the pharmaceutical industry is also interesting in its own right, since the industry is
one in which a better understanding of the importance of scope, scale and spillovers is likely to have
immediate implications for the formulation of government policy and the conduct of individual firms.
We use a panel data set with almost five thousand observations, covering more than twenty
years to explore the drivers of research productivity in the "discovery" phase of ethical drug research.
Our results suggest that there are no returns to scale per se at either the level of the firm or the level
of the research program. However we find that individual programs are more productive, all other
things equal, in larger and in more diversified firms, and that research productivity is strongly
correlated with the productivity of programs in related therapeutic areas within the firm, suggesting
that there may be significant economies of scope at the level of the therapeutic class. Our results also
suggest that research productivity in a given therapeutic class is positively associated with the patents
applied for by competing firms. We interpret these results as evidence consistent with the presence of
extensive spillovers within the industry, but we also note that they are consistent with correlated
research efforts and outcomes due to industry-wide shocks to technological opportunity.
The paper begins with a short literature review. We then briefly describe the nature of
research in the pharmaceutical industry as background to the development of some hypotheses.
Subsequent sections discuss some of the estimation issues and describe the data on which the study is
based. A discussion of the empirical results follows, and the paper closes with a discussion of their
implications and an outline of future research.
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1. Hypothesis Development and Literature Review.
Scale, scope, spillovers and research productivity.
Schumpeter (1934,1950) was the first to argue systematically that there was an enduring
relationship between firm size and research productivity. As several observers have noted, his
argument can be decomposed into several elements. In the first place, he suggested that there might
be a significant relationship between research productivity and monopoly power. Ex ante monopoly
power might serve to mitigate problems in the financial markets, while ex post monopoly power
would mitigate problems of appropriability. In the second place, Schumpeter suggested that there
may be significant economies of scale in the research production process itself, and that larger firms
may enjoy significant economies of scope. Thus he implied that not only will larger research
programs be more productive than smaller ones, but also that a research program of any given size
will be more productive if it is conducted within a larger firm.
Later work has fleshed out this idea to suggest that there may be three major advantages in
performing R&D conferred by size (Fisher & Temin (1973), Cohen and Levin, (1989)). In the
absence of fully functioning markets for innovation, larger firms may be able to spread the fixed costs
of research over a larger sales base. Larger firms may also be able to exploit complementarities
between other assets of the firm -- marketing or manufacturing expertise for example -- to increase
the productivity of research. They may also have advantages in the financial markets over smaller
firms: to the degree that they are able to mitigate problems of adverse selection and moral hazard in
raising capital, they may be better positioned to fund risky projects. Much qualitative, historical
evidence is consistent with these ideas, although a paucity of data at the program, as opposed to the
firm level, has made it difficult to distinguish between economies of scale and scope (Chandler,
(1990); Mowery (1989)).
Schumpeter's core conclusions have been challenged on two fronts. On the one hand,
organizational researchers have suggested that increasing organizational size imposes significant
diseconomies of scale in the form of increasingly bureaucratic and hierarchical organizations that
reduce technological creativity. Some industry level and case based research is consistent with this
hypothesis (Burns and Stalker, (1966); Tushman and Anderson, (1986)).
On the other hand, systematic cross-sectional studies of Schumpeter's ideas have had
inconclusive results. Much early research explored the relationship between firm size and research
intensity, seeking to explore the degree to which research intensity increased with firm size (Baldwin
and Scott (1987), and Cohen and Levin (1989), provide excellent summaries of research in this
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tradition.). The results of this work are largely contradictory, and, as Fisher and Temin (1973) have
pointed out, cannot be taken as tests of Schumpeter's ideas. Unfortunately the results of later work
exploring the more appropriate relationship between research output and firm size have been similarly
unconvincing. Bound et al. (1984) found that there was evidence of linear returns to scale for R&D
programs between $2 and $100m when patents were used as a measure of research output, but they
found that their results were quite sensitive to specification assumptions. Acs and Audretsch (1988),
using a measure of "major innovations" as a measure of output found that in highly concentrated
industries with high barriers to entry large firms were likely to be the source of the majority of
innovations, while in less concentrated, less mature industries smaller firms were likely to be more
innovative. A study by Pavitt et al. (1987), using a similar measure of output, suggested that both
very small firms and very large firms were proportionately more innovative than more moderate sized
firms. In general, as Cohen and Levin (1989) suggest, a failure to account for specific industry effects
such as variations in demand conditions, in technological opportunity and in appropriability
conditions, coupled with an inability to use project level as opposed to aggregate firm level data may
be responsible for the inconclusive nature of existing results.
The role of spillovers in determining research productivity is similarly not well understood.
Two significant practical problems make it difficult to measure their impact (Griliches, 1991). In the
first place it is difficult to distinguish between the influence that spillovers from other industries have
on research productivity through their unmeasured effect upon input costs, and the influence that they
have directly on research productivity by increasing the total stock of knowledge available to
researchers. In the second place, the accurate estimation of spillover effects is dependent on adequate
measures of technological "distance" and of R&D capital, both constructs that are exceedingly
difficult to measure. Jaffe's work (1986,1988) provides the best example of a careful attempt to
account for these problems, and his work suggests that spillovers have important effects on research
productivity, but there have been few attempts to duplicate his results using disaggregated data or
more detailed measures of technological distance.
Research in the Pharmaceutical Industry
Before turning to hypothesis development it is important to describe the nature of research
and development in the pharmaceutical industry since it has several quite distinct characteristics that
shape the determinants of research productivity (Cocks (1973,1975), Caglarcan (1978), Chein (1979),
Gross (1983), Spilker (1989)).
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Pharmaceutical drugs are chemical compounds that are introduced into humans to cure or
alleviate illness.' Ethical drugs can be usefully grouped into "therapeutic areas" such as
"cardiovascular diseases" or "disorders of the alimentary system," although some drugs, such as
aspirin, have multiple effects across several therapeutic areas. Within therapeutic classes, drugs
address particular conditions such as hypertension or peptic ulcers. To a first approximation these
more narrowly defined areas correspond to distinct "markets" but since, in general, drugs that affect a
particular organ system tend to have multiple effects, a drug may be used to treat several conditions
within a particular therapeutic class. Some of the drugs used in the treatment of hypertension, for
example, are also useful in the treatment of congestive heart failure.
Pharmaceutical research takes place in two stages: drug discovery and drug development. The
goal of the drug discovery process is to find a chemical compound that has a desirable effect in a
"screen" that mimics some aspect of a disease state in man. For example, firms might screen
hundreds of soil samples in the hope of finding a chemical compound that kills a particular kind of
bacteria, or they might test fewer carefully synthesized compounds to find out if they block a
particular enzymatic pathway. Drug discovery has become an increasingly complex process as our
knowledge of chemistry and human physiology has increased. Whereas thirty years ago a majority of
drugs were discovered through random screening, modern drug discovery relies on the integration of
knowledge from a very large number of rapidly changing scientific disciplines. Screening remains
important since it is very difficult to predict how a particular compound will react inside a biological
system, but it is now informed to a much greater extent by a detailed knowledge of scientific
disciplines such as biochemistry, molecular biology and physiology.
Individual chemical compounds, and hence particular drugs, can be patented. Although
patents can usually be effectively enforced and thus have great competitive importance, the ability to
patent a particular compound does not guarantee full appropriability of the knowledge generated
during its discovery. It is sometimes possible to "invent around" a particular patent. Rival firms can
explore variants in chemical structure in the hope of finding an equally effective compound with
fewer side effects, for example. Most importantly, the institutional structure of the industry,
particularly the very high premium placed on publication and on open communication between
scientists, means that the scientific knowledge generated in the course of a particular research
Our focus here is upon "ethical" pharmaceuticals - drugs that can only be dispensed with a
prescription.
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program is often quickly and widely disseminated throughout the industry.2
Some of the compounds identified during the drug discovery process will enter drug
development. The goal of the drug development process is to ensure that a particular compound is
safe and effective in humans. Firms apply for a permission to test a compound in humans by filing an
investigational new drug application, or "IND." If clinical trials seem successful, the company will
then submit a new drug application, or "NDA" to the Federal Drug Administration, which will then
rule as to whether the drug can be introduced commercially.3 Both drug discovery and drug
development are risky. Of approximately 1000 compounds tested in the laboratory and in animals,
less than 10 will be introduced into humans, and that of these only about 20% will ultimately be
approved (Sheck, (1984)).
Hypothesis Formulation
Although our database includes information about both drug discovery and drug development,
since the two require quite different sets of skills we focus here upon the determinants of research
productivity in ethical drug discovery.4 Given the nature of R&D in the industry, all else equal we
expect there to be significant economies of scale and scope in performing R&D, and we expect
research productivity to be affected by both internal and external spillovers.
Returns to scale flow from two sources: from the ability to spread fixed costs out across a
larger effort and from the ability to invest in specialized skills or more efficient techniques as the size
of the effort increases. Conventional wisdom in the pharmaceutical industry suggests that beyond a -
minimum threshold size, under most circumstances there is little to gain from increasing the size of an
individual discovery program, and our descriptive statistics (see below) certainly confirm this
conclusion in outline. However since pharmaceutical research often requires investment in substantial
2 Not all firms place a high premium on publication, and major biological discoveries are more likely
to be published before major chemical discoveries. However the industry remains a strikingly "open" one
in comparison to the majority of technologically driven industries.
3 The process described here is in use in the United States: a comparable process is required by
nearly every other developed nation.
4 Drug discovery is fundamentally a scientific process requiring the integration of complex scientific
knowledge across a wide range of disciplines. Successful drug development, in contrast, requires the
management of a program of clinical testing that is often initiated world wide using a diverse group of
medical practitioners, and the integration of a far wider range of business functions, including toxicology,
product formulation and process development (Spilker, 1989).
6
t4%
11
fixed costs and since the complexity of the underlying science offers considerable scope for
specialization, we expect significant economies of scale at the level of the firm. For example, to the
degree that legal and regulatory expertise are fixed costs, a larger research effort will gain economies
of scale by spreading them over a larger base. A larger R&D effort might also be able to afford to
invest in more highly specialized individuals or facilities. Whereas a smaller research and
development effort might need to employ molecular biologists who can work across a relatively wide
range of fields, for example, a larger one might be able to afford more narrowly focused specialists.
We also expect there to be significant economies of scope. Economies of scope exist when a
tangible asset or a human resource can be used in more than one application at no additional cost.
Consider, for example, the benefits of investing in a centralized laboratory devoted to peptide
chemistry. Economies of scale exist if the costs of the laboratory are partially fixed, and if the lab can
serve a larger and larger discovery effort for a less than proportionate increase in cost. They will also
exist if the laboratory can become more efficient as it has more work to do, possibly through the
specialization of its members. Economies of scope exist if the work of the peptide chemists is
potentially relevant to a wide range of applications, and can be utilized in any one of them without
diminishing its usefulness in the others.5 Economies of scope may also arise if there are internal
spillovers of knowledge, and the results of successful research in one field have implications -for work
in other fields.
Thus in general, while we expect economies of scale at the level of the firm to be simply
related to the total size of the discovery effort, economies of scope should be related to the range and -
diversity of the research programs undertaken by the firm. Notice that it is difficult to distinguish
between the benefits of economies of scope that arise from cost (or risk) sharing and the benefits of
internal spillovers. Conceptually, a clear distinction can be drawn between spillovers, in the sense that
research input in one area may generate knowledge or research results applicable to other areas
(research in neurochemistry directed towards diseases of the central nervous system may generate
compounds which turn out to have clinical application in anti-spasmodics), and economies of scope
arising from the public goods aspects of core bodies of knowledge applicable to many fields (peptide
chemists). In practice, both effects are likely to be a function of the diversity of the firm's research
activities and the linkages between them.
5 The aggressive exploitation of a well established brand name by companies such as Coca-Cola
and Johnson and Johnson is another well known example of the presence of economies of scope.
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At both the level of the firm and the level of the research program, economies of scale and
scope will flow from the firm's ability to invest in increased levels of specialization and to spread the
fixed costs of scientific expertise across a wider base of research. The relative size of the two effects
will depend upon the degree to which both the tangible resources and the less tangible knowledge
upon which drug discovery is based are exclusively useful to a particular research program (or
broader therapeutic area) or to the process of drug discovery in general. We thus expect economies of
scale at the level of the research program to vary across fields, and economies of scope to vary by
firm as firms pursue different mixes of research programs.
Research productivity may also be affected by the efforts of competing firms. On the one
hand, firms may be "racing" with each other to reach a particular target, so that, all other things
equal, research productivity will be negatively correlated with competitors' investments (Reinganum,
(1989)). In the extreme, firms will keep entering the race until all of the potential (privately
appropriable) benefits of the new drug will be dissipated by the costs of competing research (Dasgupta
and Stiglitz, (1980)). On the other hand, firms may benefit from competitor's research since, all other
things equal, if there are extensive spillovers between firms, the productivity of a research team may
increase as others work in the same field. For example, when Bristol-Myers Squibb announced that
they had found an orally active ACE inhibitor, "Captopril," a potent hypertensive therapy, several
competing firms were able to take advantage of their knowledge of Captopril's chemical structure to
focus their own research efforts. If there are significant spillovers in the industry, a belief certainly
consistent with the qualitative evidence, then competitive investment will increase the marginal
productivity of investment in the industry.
In both theory and practice, of course, these two effects interact with each other in complex
ways (Spence (1984), Dasgupta and Stiglitz (1980), Baldwin and Scott (1987), Reinganum (1989)). In
our companion paper "Racing to Invest?: The Dynamics of Competition in Ethical Drug Discovery"
we explore this issue in more detail. For the purposes of the analysis presented here, we hypothesize
that, all other things equal, a positive correlation between research success in any given area across
competing firms is consistent with the presence of significant spillovers or research complementarities
between firms, while a negative correlation is consistent with a research environment that is primarily
driven by racing behavior.6
6 This conclusion must be carefully qualified: our discussion has assumed that scientific opportunity
- the base case relationship between effort and the odds of obtaining a drug - is constant across these
regimes. If scientific opportunity changes in ways that we can not observe using our data, then a positive
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Prior Research in Pharmaceuticals
Existing studies of the determinants of research productivity within the pharmaceutical
industry provide some support for these hypotheses but have been hampered by a reliance upon
aggregate, firm level data. A majority have used new drug applications or new drug introductions as
their primary measure of output, and firm level data that does not discriminate between research
programs or between spending on discovery and development. These studies suggest that prior to
1962 there were significant diseconomies of scale but that since 1962 larger firms have enjoyed
important economies of scale in research and development (Comanor (1965,1986), Baily (1972),
Cocks (1973), Vernon and Gusen (1974), Grabowski et al. (1978), Schwartzman (1976), Wiggens
(1979), Jensen (1987).) Most of these studies interpret this result as suggesting that the increased
regulatory stringency that followed the 1962 amendments to the Food and Drug act gave an advantage
to larger firms in allowing them to exploit economies of scope in dealing with the regulatory
authorities. There has been little systematic exploration of the role of spillovers in the industry, with
the notable exception of work by Dranove and Ward (1991) and Arora and Gambardella (1991). This
work suggests that spillovers are important, but the limitations of their data allowed them only to
explore their implications at the aggregate level.
2. Specification of the Econometric Model
The measurement of "true" research productivity is a project fraught with well known
problems (Griliches (1984)). In the ideal case, we would like to measure the social as opposed to the
private returns to research. Unfortunately the problems of measuring the social returns to investment
in pharmaceutical research are likely to be particularly acute because prices for pharmaceuticals may
not reflect the functioning of an efficient market.7 Even private returns to R&D investment in this
industry are difficult to estimate: the economic returns realized by firms are the final result of a
lengthy and uncertain process, driven by the uncertainties of clinical testing, the complexities
introduced by marketing, competitive activity and the role of the forces that determine the demand for
correlation of either investment in research or of research success across competing firms may reflect an
increase in scientific opportunity, rather than the presence of spillovers. We return to this point in the
interpretation of our results.
7 The attempted measurement of social return through hedonic analysis of pharmaceutical
characteristics and pricing is underway in studies by Ernie Berndt at MIT and Valerie Suslow at
Michigan.
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new therapies, as well as by scientific discovery at the laboratory bench. These problems are
compounded by substantial difficulties in estimating costs of capital and in making appropriate
adjustments for risk (Di Masi, (1991); Grabowski and Vernon, (1978)).
Our objectives in this paper are more modest. As a first step towards building a quantitative
model of research productivity, we focus on the determinants of "technical success" in drug
discovery, as measured by patent grants. Pharmaceutical companies patent prolifically, and patents
are, of course, a rather noisy measure of research success, in part because the significance of
individual patents varies widely. We control for this by counting only "important" patents, where an
"important" patent is defined as one that was granted in two of the three major jurisdictions: Japan,
Europe and the United States. We think of these patents as a useful measure of the generation of new
knowledge, which is the "raw material" input to subsequent stages in drug development. Patents are
clearly only one possible measure of success, and later work will explore the use of IND counts,
NDA counts, sales and market share as alternative measures of research output. But our interest here
is on determinants of technical success, defined in terms of producing new potentially important
compounds, rather than on the ultimate commercial success or failure of new drugs, for which patent
grants based on Patent Examiners' slowly changing objective criteria of novelty, non-obviousness, and
potential industrial application, are one reasonable measure of research output.8
Though the findings may not speak directly to the question of what determines economic or
commercial productivity, we believe them to be an important contribution to further progress in
understanding R&D in pharmaceuticals. Research results in programs which are not subsequently
successful in the clinic may be valuable to other firms, in other fields, or in later efforts in the same
program, and thus insight into their generation has broader implications. We believe that it would be
misleading to base our analysis on the ex post success of a few blockbuster drugs.
We hypothesize that patent counts are generated by a production function Y = f (X,5) ,
where Y is patent counts, X is a vector of inputs to the drug discovery process, and is a vector of
parameters. We have no priors about the "true" functional form, so the model estimated should be
8 Since firms may differ in their patenting strategies, or in their "propensity to patent," care should
be taken in interpreting our results. We include firm dummies in our models to control for differences
between firms that persist over time, but in general our results are most robustly interpreted in terms of
marginal effects upon patent output.
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thought of as a local approximation.
Some previous studies have looked at the dynamics of the R&D/patents relationship by
estimating a lag structure on the input variables. Rather than make assumptions about distributed lags
(and have to throw out much of our data in order to have 4 or 5 lags present in every program) we
simply include "stocks" of the input variables as explanatory variables. The annual flows are
reasonably smooth, so this is equivalent in many senses to imposing a geometric lag structure, where
we have assumed a depreciation rate rather than estimated one. Notice that given a smooth series for
the flow variable, it will be difficult as a practical matter to identify the estimated coefficient on the
stock variable separately from the depreciation rate, making our assumption of a particular
depreciation rate a second-order problem.
Since the dependent variable in this relationship only takes on non-negative integer values,
some type of discrete dependent variable model is dictated. We assume that patent counts are
generated by a Poisson process, which is appropriate if we are prepared to model research results as
the outcome of an unknown (but large) number of Bernoulli trials with a small probability of success.
This model certainly captures some aspects of drug discovery, such as screening. It may be less
appropriate for mechanism-based research.
We model the single parameter of the Poisson distribution function, X, as a function of some
explanatory variables, X, and parameters in the standard fashion:
E[Y,] = ,t = exp(Xfl)
to guarantee non-negativity of X, and estimate the parameters by maximum likelihood in the standard
way. Note that the choice of whether to use explanatory variables in levels or logs has important
implications in this model. If we use levels, the estimated elasticity of output with respect to each
explanatory variable will vary with the magnitude of the variable by assumption. Conversely, if an
explanatory variable enters in logs we impose the constraint that the elasticity is constant over its
range of variation. In the case of R&D, we prefer to maintain the null hypothesis of constant elasticity
of Y with respect to R&D expenditures 9 allowing easy comparison with previous work. Since we
have a fair number of observations in which the R&D variables are zero, using the log of the R&D
variables introduces the complication that we cannot take the log of zero. Following previous work,
9 In exploratory work-we tested for non-linearities in this relationship by including separate quadratic
terms in the log of R&D. Estimated coefficients were very small and insignificant.
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we deal with this by setting the log of R&D equal to zero in such cases, including an appropriately
coded dummy variable to account for this in the regression. We have no strong priors about the
appropriate way to include the other explanatory variables and we report results obtained by entering
these variables in levels. Many of these variables also have substantial numbers of zeros, and this
avoids numerical problems in the estimation caused by near collinearity of the VARIABLE=O dummy
variables with other regressors.10
A useful way to think about this specification is to divide the explanatory variables into two
classes: the R&D variables, R, and other variables, Z, (which include spillovers, measures of scope
and scale, plus the constant term and firm and therapeutic class dummies). The estimated function has
a direct proportionate relationship between R&D expenditures and patent counts, mediated by a
multiplicative "shift variable" which will vary according to the extent of spillovers etc.
E[Y,] = X = exp (llog (Ri,) +-yZ,)
= Ri, · exp(yZ;,)
Re-writing the equation in logs,
log(X,) = log(R,) + Z,
thus we can interpret the coefficient on log(R) directly as the elasticity of Y with respect to R&D,
while the elasticities of the Z additional variables are yZ.
The assumption that the dependent variable is distributed Poisson is quite strong: like most
other data of this type, the mean=variance property of the Poisson distribution is violated here. In the
presence of such overdispersion, though the parameters will be consistently estimated, their
standard errors will typically be under-estimated, leading to spuriously high levels of significance.
Overdispersion is often interpreted as evidence that the statistical model is misspecified in the sense
that there may be unobserved variables in the equation for X,
E[YI,] = Xi, = exp(XI,+e,)
As is well known (see Hausman, Hall, Griliches (1984), Hall, Griliches, Hausman (1986)) if is
distributed gamma, then it can be integrated out giving Y distributed as a negative binomial variate. If
e is not truly gamma, however, then the maximum likelihood estimates of the coefficients of the
'o Very similar results were obtained in exploratory work using all explanatory variables in logs.
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model will be inconsistent. Gourieroux, Montfort, and Trognon (1984) suggest using a quasi-
generalized pseudo-maximum likelihood estimator based on the first two moments of the distribution
of Y, which gives consistent estimates for e drawn from a wide variety of distributions. The GMT
estimator is just weighted non-linear least squares estimates of the NLLS model
Y/ = exp (Xi,) + i,
with weights derived from the relation VAR[Y] = E[Y] (1 +7 2 E[Y]) using initial consistent estimates
of 5. Below we present alternate estimates of some of our regression models using maximum-
likelihood estimation of the Poisson and Negative Binomial models, non-linear least squares (with
robust standard errors), and the GMT estimator.
3. Sources and Construction of the Data Set.
This paper uses a data set obtained as part of a larger study of research productivity in the
pharmaceutical industry. The larger study has both qualitative and quantitative components. The
qualitative study draws upon the medical and scientific literature and upon a program of detailed field
interviews, and is designed both to shape the choice of variables and hypotheses explored in the
quantitative study and to explore the role of less easily measurable factors such as organizational
structure and firm culture in driving research productivity.
The quantitative study draws upon data about spending and output at the research program
level obtained from the internal records of ten pharmaceutical firms. Although for reasons of
confidentiality we cannot describe specifics of the overall size or nature of the firms, we can say that
they cover the range of major R&D-performing pharmaceutical manufacturers, that they include both
American and European manufacturers, and that we believe that they are not markedly
unrepresentative of the industry in terms of size, or technical and commercial performance. This
section offers a brief description of the important variables used in the econometric analysis, and
discusses descriptive statistics for the data set.
The data set used in this paper is an unbalanced panel of 4879 observations, indexed by firm,
research program, and year. With a complete, rectangular, panel we would have 11,400 observations,
made up of ten firms, 38 research programs, and up to 30 years of data. In practice not all of these
observations are available: the average time period for which we have complete data is on average
just under 20 years per firm, and not all firms are active in all research areas. Our working sample is
drawn from a data base which currently has 5543 potentially useful observations. After deleting
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missing values, grossly problematic data and peripheral research areas we are left with 4879
observations. The number of observations per firm varies from over 1000 to less than 100, with a
mean of 554.3. For each observation we have data on both inputs and outputs to the research process.
Our measures of input include person years and research spending in discovery and development, and
our measures of output include patents, INDs, NDAs, new drug introductions, sales and market
share.
Assembling the data in a consistent and meaningful format required considerable effort. In
nearly every case the process of data collection was an iterative one, involving close collaboration
between the researchers and key personnel from the participating companies. The majority of the data
were collected specifically together for the purposes of this study. Each firm spent some months
assembling the data, usually from primary documents, and the full data collection effort took nearly
two years. We worked hard to ensure that, as far as was possible, definitions of research program and
of expense grouping were standard across firms, data was collected at the same level of aggregation,
and overhead expenses were treated in a consistent way.
Data was collected by research program rather than by therapeutic class or by project since
analyzing the problem in this way best reflects the dynamics of discovery research. A grouping by
therapeutic class is too general: "cardiovascular research," for example, includes research into widely
different areas such as hypertension, cardiotonics, antiarrhythmics and hyperlipoproteinemia.
However analysis of data by individual project is difficult and misleading. Not only is it difficult to
assign effort to particular drug candidates with any accuracy, but the notion that research productivity
is best measured at this level raises serious conceptual difficulties. A research program typically
continues over many years. At the discovery stage, the firm invests in the program, rather than in
particular candidates. The identification of a drug development candidate is an indication of the
success of the program, and retrospectively assigning resources to its generation may introduce
serious biases into the analysis.
Classification of our data into therapeutic areas is an important factor in our analysis, since it
drives both the fundamental organization of our data, and the notion of spillovers." Note also a
crucial distinction drawn between two tiers of aggregation: a detailed "research program" level, and a
more aggregated "therapeutic class" level which groups related programs into therapeutic areas. For
" We classified our data into therapeutic areas according to a scheme which closely follows the IMS
Worldwide classes. A more detailed discussion of this issue is contained in Appendix One, and a
complete listing of therapeutic classes is given in Appendix Two.
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example, the therapeutic class "CARDIOVASCULAR" includes the research programs "ANTI-
HYPERTENSIVES", "CARDIOTONICS", "ANTITHROMBOLYTICS", "DIURETICS" etc.
Full details of the construction of variables used in the study are given in the Appendix. Our
primary variables are DISCOVERY, defined as "expenditure relating primarily to the production of
new compounds", which excludes clinical development work and is measured in constant dollars; and
PATENTS, a count of "important" patents. These measures of inputs and outputs are matched by
year and research program. We count patents by their year of application, and define "importance" by
the fact that the patent was granted in two of the three major markets: the USA, Japan, and the
European Community. Applying this criterion screens out large numbers of patents: up to 60% of the
number filed in the US in any given year are discarded. The first year in which we were able to
obtain this data is 1961, and although we have data for 1989 and 1990, we believe that these are
seriously undercounted. Patent grants may lag applications by as much as four years in the United
States and six in Japan. Our data were obtained from files current in 1992, and since we are counting
patents by year of application, many of the patents applied for in 1989 and 1990 may not yet have
been granted, and our final sample therefore includes only observations for the years 1961-1988.'2
We tried our best to ensure that the DISCOVERY variable was measured consistently across
research programs and across firms, despite serious differences in accounting conventions and
reporting formats across firms and over time, and we took steps to ensure that, wherever possible, the
data covered worldwide research spending, not just US facilities.
We also construct measures of the overall size of the firm's R&D effort and of the scope of
its activities. -SIZE is total discovery spending that year,- which is intended to capture the effects of the
overall scale of the firm's research effort.' 3 SCOPE is a count of the number of narrowly defined
research areas in which the firm is active, in that it spent more than $500,000, in constant 1986
12 Several industry experts have suggested that this is an unsatisfactory measure of "importance"
in that many purely "defensive" patents are filed in at least Europe and the U.S. They suggest that a more
appropriate gauge of importance would be filing in fifteen or twenty counties. There may also be
important differences in the patenting policies of European vs US firms. However preliminary analysis
using INDs as a measure of output suggests that our measure of patents is significantly correlated with
INDs, confirming us in the belief that we are capturing an important dimension of performance.
13 There are some grounds for believing that the relevant measure of size is the scale of the entire
firm, captured by e.g. total sales, or total employees. We experimented with these types of measures in
exploratory work, but obtained poor results. These are perhaps not too surprising given that size effect
captured by a variable such as total firm sales is likely to be seriously confounded with e.g. demand.
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dollars, in a single year. This variable is intended to capture the effects of the firm's diversification
into different therapeutic areas. Note that SCOPE and SIZE are unique only to firm and year, not to
firm, year, and research program.
We then construct variables intended to capture the effects of spillovers both within and
between firms. For each observation on firm and research area, we start with the basic data on "own"
annual flows of inputs and outputs. We then construct spillover variables at two levels. We capture
spillovers internal to the firm by measuring the output of all of the other research programs within the
relevant therapeutic class. We measure spillovers between firms using the output of 29 other firms,
both in the observation's own narrow research area, and in the wider therapeutic class. 4 Finally,
we construct "stocks" for all of these variables by accumulating the flows over time with a 20%
depreciation rate, and also a "news" variable by subtracting 20% of the stock at the beginning of the
year from the annual flow.
Descriptive Statistics
Tables (1) and (2) and Figures (1),(2) and (3) present summary statistics describing these
data. The first five columns in Table 1 are for our full set of data with up to 5543 observations on
each variable, and are "case-wise" calculations based on each variable's non-missing observations.
Means for the sample of 4879 observations used in our regressions which is obtained by "list-wise"
deletion and imputation of zeroes for some missing data, are given in the last column.
Averaging across all firms, research programs, and years, our firms spent on average $1.99m
1986 dollars on discovery per program per year for an average of 1.7 "important" patents. Each
"important" patent, on average, thus cost about $1.2m in 1986 dollars. The average firm in our
sample is highly diversified, investing substantially (more than half a million dollars) in just over ten
programs a year. In addition firms invest more than ten thousand dollars a year in a further six
programs.
All of the key variables show a substantial amount of variation. Discovery expenditures per
class per year have grown substantially for the firms in our data set, from $730,000 1986 dollars per
'4 We chose as our sample the ten firms that have given us data together with 19 other firms who
have been consistently in the top 40 world wide pharmaceutical firms in terms of R&D dollars and sales.
Note that these 19 firms are only a fraction of the population of other firms generating spillovers, and
the estimated coefficient on our external spillover variables may therefore tend to overstate the magnitude
of this effect. However we believe that these firms are a representative sample of the industry as a whole,
and account for the majority of the industry's spillover pool.
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class per year in 1964 to $4.2m 1986 dollars per class per year in 1990 (Figure 1). At the same time,
our data suggest that there has been a secular decline in the number of patents granted per program
per year since the late 70s. (Figure (1).) This decline may be an artifact of our definition of
"important" patents, since in many cases patents do not issue in Japan until quite late in the lifetime
of a product, but it may also reflect the general decline in patenting rates that has characterized US
and European firms over the last five years.' 5
Perhaps the most dramatic effect visible in the time series aggregates of our data is the huge
increase in the costs of pharmaceutical research: the average firm in this sample's total investment in
discovery research more than quadrupled in real terms from $16m constant 1986 dollars in 1964 to
almost $67m constant 1986 dollars in 1990, reflecting increased intensity of highly skilled manpower
in R&D and very substantial increases in the complexity and sophistication of research methods,
equipment, materials etc. This aggregate figure masks some important movements in the program
level data. While there was a very significant "deepening" of individual research programs (real
discovery spending per program rises by almost 600% over the same period), this was accompanied
by changes in the scope of the average firm's activities: the number of half million dollars plus
programs in our average firm's portfolio rises by 31%, from 8.2 to 10.7, and concomitant movements
in the numbers of smaller programs active in any given year. (See Figure (2).) It should be noted
though that the variation in SCOPE of the whole sample is driven largely by differences between
firms, rather than within firms. In fact SCOPE varies rather little within firms, with only the most
diversified firm having a CV (std/mean) of more than 0.3, suggesting that it is likely to be difficult to
distinguish between scope and firm effects in subsequent analysis.
The size distribution of discovery expenditures per research program per year, presented in
Figure (3), is also interesting. For over 44% of the program-years in our sample, no expenditures on
discovery were recorded.' 6 Of the remainder, about one quarter of cases involved spending less than
$0.2m 1986 dollars per program per year, and about one half spent less than $0.8m 1986 dollars per
program per year. At the other tail of the distribution, just under 2% of cases involved expenditures
'5 This in turn may not reflect a real decline in inventive activity, but institutional factors such as
resource constraints imposed on patent offices. See Griliches (1991).
16 To the best of our knowledge these are "genuine" zeros and reflect intermittent expenditures over
time, or programs which were "alive" in that they were spending money on development. Deleting these
observations from the data set does not substantially change either the magnitude or the significance of
our estimated coefficients.
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of more than $10m 1986 dollars per program per year. There are also very substantial differences in
the average level of expenditure across therapeutic classes: mean discovery expenditures per program
range from $940,000 per year in alimentary tract and metabolic research to $4.0m per year in
cytostatics.
On the output side, the distribution of annual counts of important patents per program (Figure
(4)) is highly skewed to the left. About half of our observations show zero output per program-year,
and almost 90% of the counts are less than 5 per year. Patent counts also vary significantly across
firms, across therapeutic classes and across time. While the mean number of patents per program is
1.7 per year, this varies across firms from 3.1 to 0.09 per year, and across therapeutic classes from
0.7 per year for work in the genito-urinary system to 3.7 per year for cardiac and circulatory
products.
4. The Empirical Results.
Analysis of aggregate data.
As a preliminary step in the analysis, Table (3) presents results obtained by aggregating our
data to the firm level to explore the effects of scope and scale. This aggregated version of our data is
a rather small sample, with only 181 observations on our 10 firms, and results should be therefore be
treated with caution. Specifications (1) and (2) are Poisson regression estimates of "important" patents
on flow and stock values of DISCOVERY, a quadratic time trend, and firm dummies. (Nonsensical
results were obtained without the time trend, which is included in all our models.) The implied long*
run elasticity of "important" patent output with respect to research spending in model (2) is about 0.4,
somewhat lower than, but not inconsistent with, the results obtained for much larger samples of firm
level data by e.g. Bound et al. (1984), Hausman, Hall, and Griliches (1984) and Hall, Griliches and
Hausman (1986).'7 This elasticity is well below 1, suggesting that there are not increasing returns to
scale in drug discovery at the firm level. Note that these results suggest that firm effects are a very
important determinant of innovative performance. Including firm dummies more than doubles the log-
likelihood function, and failing to control for firm effects, as in model (1), gives a puzzlingly low
coefficient on contemporaneous R&D, indicating that this version of the model may be badly miss-
17 There are two important differences between this work and previous studies which make these
results not strictly comparable. Firstly, we have distinguished between discovery and development
expenditures, and secondly, our patent counts are restricted to "important" patents.
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specified. In equations (3) and (4) we use our knowledge of the number of active research programs
within each firm to investigate the presence of returns to scope. In equation (3) our measure of scope
enters the regression linearly, with an implausible negative coefficient. Our preferred model allows
for diminishing returns to increasing scope by including a quadratic term, giving us a more plausible
inverted-U relationship between scope and research productivity. The final column of Table (3)
presents results conditioning on past innovative success by including the stock of past patents. The
coefficient on R&D stock falls somewhat, but the results on scope are largely unchanged.
Thus, in aggregate, our data appear to reflect the general cross sectional result: there is no
evidence of returns to scale per se in research: increasing R&D intensity in and of itself does not
produce a more than proportionate increase in innovative output. The results do however suggest that
up to a point, size may confer substantial benefits: at the mean, an increasing the size of the total
research effort by 10% (an amount equivalent to adding an additional program) is associated with a
3 % increase in the patent output of existing programs.
If we did not have access to program level data we might stop here, noting that this result is
consistent with the qualitative evidence that suggests that there are limited returns to increasing the
size of research programs, and that the returns to scale in the industry suggested by the recent wave
of mergers and by the results of scholars such as Baily (1972), Cocks (1973), Comanor (1965) and
Jensen (1987) are driven by and by economies of scale in activities "downstream" from discovery
research, notably in clinical development and in the regulatory arena.
Analysis of Program Level Data
The results of our analysis of program level data are given in Tables (4), (5) and (5a).
Table (4) shows the results from re-estimating variants of the equations in Table (3) at the
disaggregated research program level. Again, the dependent variable is "important" patent
applications and the models were estimated using Poisson regression.
Two core findings are immediately apparent. Firstly, there is a statistically significant
relationship between inputs and outputs in these disaggregated data. Although prior research has
shown that there is a statistically significant relationship between inputs and outputs at the firm level,
it is reassuring to find that at the research program level there is more in the quantitative data than
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simply noise.18
Secondly, there are very significant differences in research productivity across therapeutic
classes and between firms. In these data we are able to control for an important source of
heterogeneity in the data by including therapeutic class dummies (defined at a somewhat higher level
of aggregation than our "program" unit of observation) as well as controlling for fixed firm effects.
Likelihood ratio tests on excluding firm and therapeutic class dummies are highly significant, and
interaction effects on discovery spending show large differences across firms and therapeutic
classes.' 9 Note that while firm dummies account for a substantial amount of the variance in the
dependent variable, the R&D elasticities do not change much when they are included in the model. By
contrast the coefficients on the R&D variables fall by about a third in equation (8) when the class
dummies are included. This suggests that an important part of the "firm effect" identified in the
aggregate data and the results presented in Table (4) lies in the firm's choice of research programs.
Just as in the firm level results, SCOPE has a significant and non linear impact on research
productivity. In these data we are also able to test for scale effects derived from the total size of the
research program: the SIZE variable enters with a positive and significant coefficient in equation (12),
which increases somewhat when we control for SCOPE in equations (13) and (14). The final equation
in Table (4) conditions on past success (or innovative capabilities) by including the stock of past
patents. This variable is highly significant, and induces a correspondingly large drop in the likelihood
function. The coefficient of 0.035 corresponds to an elasticity of about 0.25 at the mean. The SIZE
and SCOPE effects are unchanged, but the coefficients on R&D fall sharply. We interpret this as
being consistent with the hypothesis that patent applications are driven by the available stock of
knowledge capital, and that the better measure of this stock is innovative output rather than innovative
input. It may also however reflect two specification problems: the patent stock variable may be
proxying for a variety of unobserved correlated effects, or there may be a problem with the
exogeneity of the R&D variables with respect to patents. Conditioning on past success may simply be
18 The very substantial increase in the log likelihood as we add variables to the model corresponds
to an R2 in excess of 0.5 which corresponds favorably to typical panel data results using micro data.
"9 With both firm fixed effects and therapeutic class fixed effects we are quite close to estimating a
non-linear panel data model with fixed effects. While we believe that is important to control for these
effects at these levels of aggregation, the large numbers of dummy variables (10 firms and 16 therapeutic
classes) limits our ability to obtain stable estimates if we try to, for example, use time dummies instead
of a non-linear trend.
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purging the R&D coefficients of the part which is the endogenous response to past success.
In Table (5) we introduce our measures of internal and external spillovers. (The first column
of Table (5) simply duplicates the last column of Table (4) to allow easy comparison.) In exploratory
work we included both flow and stock versions of these variables in the model, but concerns about
the presence of measurement error (in many cases the coefficients were equal but opposite-signed
suggesting that they were picking up the same underlying factor) led us to use the "news" formulation
presented here, in which news in X is given by N, = X,-6K,_ 1 where K is the stock of X and 6 is
the depreciation rate. This construction reduces the measurement error problem and has an
informative interpretation: own research productivity is higher when the output of spillover sources
"spurts" beyond the level required simply to maintain their previous stock. Equation (15) includes a
measure of internal spillovers: "news" in the output of related programs within the same firm, which
enters with a positive and strongly significant coefficient. An alternative, and perhaps less
satisfactory, measure of internal spillovers is effort in related classes (as measured by discovery
spending) which we introduce to the basic model by itself in equation (16), and in conjunction with
the output-based variable in equation (17). By itself, the effort variable is positive and marginally
significant, but the "news in related patents" knocks it out completely in (17) and we drop it from
further consideration.
In equation (18) the basic model is augmented with measures of external spillovers from
outside the firm, both from within the narrowly defined research area, and from related therapeutic
classes. Both enter with positive and significant coefficients, with elasticities of about 0.1 at the mean.
Re-introducing the internal spillovers variable in (19) completes our "preferred" model, which
captures the following effects: a rather low elasticity of research output with respect to R&D spending
(about 0.1 in the long run); a positive effect on research productivity from increasing the scope of the
firm's research activities (up to a point); a positive effect from increasing the overall scale of the
research effort; a very significant effect of past research success on current performance, and positive
effects of spillovers from both within the firm and from the research output of competitors.
Table (5a) addresses some of econometric issues raised previously by presenting alternative
estimates of equation (19) using the various statistical models discussed in section 2. (Again (19) is
duplicated from the previous table to allow easy comparison of results.) Equation (20) gives Negative
Binomial estimates, where the variance is modelled as an increasing function of the mean',
20 Cameron and Trivedi's (1986) Negbin II model.
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equivalent to adding an unobserved gamma distributed random program effect to the model.
Coefficients are broadly comparable to those obtained in the Poisson model, with slightly inflated
standard errors, though the coefficients on stock of patents and current R&D rise quite substantially.
Equation (21) is the non-linear least squares model, Y = e- +e , with robust Eicker-White standard
errors. In this model, the R&D variables lose their significance altogether (and the coefficient on
R&D stock falls by a factor of 4) though the other results carry through from the Poisson
specification. Finally, (22) gives the results from the weighted NLLS GMT estimator which if the
exp(X3) part of the model is correctly specified, will give consistent and efficient parameter
estimates.21 Results are broadly comparable with the Poisson estimates, with slightly larger standard
errors, though the coefficients on the R&D variables are somewhat higher.
5. Conclusions
Previous research has suggested that large firms may have an advantage in R&D competition
arising from their ability to exploit economies of scope and scale in conducting research. However
little systematic work has attempted to distinguish between the effects of scale and scope, and cross
sectional studies using firm or line-of-business level data have found no simple relationship between
size and research productivity. Our results confirm that moving within the firm through the use of
detailed program level data may significantly improve our understanding of the relationship between
scale, scope, spillovers and research productivity.
In line with previous studies of the pharmaceutical industry, we find no evidence of increasing
returns to scale or scope at either the program or the firm level. We do however find evidence for
complicated relationships between scale and scope and research productivity which are non linear and
embedded in the structure of the research portfolio, and thus very difficult to pick up in aggregate
firm level data.
"Up to a point," we find that research programs conducted within large firms will be
significantly more productive those conducted within smaller firms, all other things equal. We identify
three main advantages to running larger research efforts: economies of scale, economies of scope, and
enhanced absorption of internal and external spillovers. The marginal effects suggested by our
21 The GMT estimates were calculated with weights derived from the Poisson estimates of , rather
than from unweighted NLLS. These give estimates of t/2 which are in line with the overdispersion
parameter estimated in the Negative Binomial model. Using the NLLS Os gave an implausibly low
estimate of t/2 of 0. 11, and the resulting GMT weighted NLLS results were very difficult to interpret.
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regression coefficients are difficult to interpret because SIZE, SCOPE and the program size are not
independent. To get a sense of magnitudes, relocating the "average" program into a firm of twice the
size would increase its productivity by 12%. Similarly, moving it from one of the least diversified
firms into a firm running twice the number of programs would increase its productivity by about 20%
through scope economies alone. This understates the return to diversification since the move to a
more diversified firm will also increase the program's productivity through the absorption and
generation of additional intra-firm spillovers.
Our results also suggest that inter-firm spillovers play an important role. "Own" research
productivity is significantly positively associated with competititors' success in related research. A
10% increase in the flow of patents in related areas at other firms generates an expected increase in
patent count of around .7%. While this number may seem small, recall that these cross firm spillovers
operate across the entire industry, so that the aggregate effects of on industry productivity may be
quite high. If we knew that it was always equally difficult to get patents, our results would be
consistent with the hypothesis that the effect of spillovers in the industry are such as to make the
social rate of return to research significantly higher than the private rate of return. However we
cannot conclude this from our results, since our coefficients estimate the net effects of scientific
opportunity, investment behavior and the presence of spillovers. If investment behavior reflects a
sudden change in the scientific opportunities in a particular field, for example, then our results are
consistent with the hypothesis that when scientific opportunities in an area dramatically increase, both
investments in discovery and the rate of patenting also increases. We explore this issue in more detail
in our companion paper "Racing to Invest?: The Dynamics of Competition in Ethical Drug
Discovery."
While the specifics of our results cannot be unilaterally extended to other industries, they do
suggest that a very significant component of the firm effect evident in previous studies of research
productivity is precisely the size and shape of the research portfolio. This is a finding that has
fundamental implications for the larger question of the theory of the firm. It has long been known that
in general minimum efficient scale in production cannot explain observed firm sizes (Panzar, 1989),
and our results lend support to those that have argued that one of the most important determinants of
firm size and scope in research intensive industries is the opportunity to take advantage of intra-firm
spillovers of knowledge (Chandler, 1990; Teece, 1988).
The heterogeneity we observe across the firms in our sample in innovative performance
reflects significant variation in their responses to sharply rising costs of doing research and the
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increasing role of core bodies of knowledge about physiological mechanisms. While SIZE rose
substantially for every firm in the sample, firms "grew" their research portfolios in very different
ways. Though we cannot be specific, due to confidentiality issues, we note that while some firms held
SCOPE (as captured by our rather crude measure) constant and simply increased their average
program size, others held program size roughly constant and grew by adding new programs, others
grew in both dimensions, and some chose to reduce SCOPE and greatly increase program size. At the
same time, the firms in our sample employed quite different organizational structures in an attempt to
ensure that the potential of both intra-firm economies of scope and inter-industry spillovers were fully
realized. Pursuing these different strategies had, we believe, quite important consequences for their
innovative and financial performance. We are actively exploring this issue in our research.
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Figure (1):
Patenting rates per program over time
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Figure (2):
The Evolution of Scope and Size
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Figure (3)
Discovery/program, Frequency Distrib.
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Figure (4)
Patents/program frequency distribution
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Descriptive Statistics: Means of Selected Variables By Year
DISCOVERY:
Spending per
program,
1986 $m
0.42
0.61
0.69
0.73
0.77
0.87
0.96
1.14
1.18
1.40
1.45
1.55
1.67
1.86
1.82
1.83
1.97
2.15
1.96
2.07
2.25
2.32
2.45
2.25
2.50
2.63
3.01
3.53
3.73
4.16
Own
PATENTS
per
program.
0.99
0.90
1.30
1.39
1.44
1.47
1.28
1.74
1.38
2.26
1.82
1.88
2.39
2.75
2.73
2.91
2.59
2.84
2.06
2.04
1.70
1.53
1.64
1.55
1.79
1.25
0.97
0.51
0.30
0.08
SIZE:
Total discovery
spending by this
firm, 1986 $m
7.08
12.81
14.60
16.24
18.72
22.61
24.36
27.69
28.72
31.65
34.57
29.14
31.60
34.49
31.38
30.58
30.57
31.14
28.42
31.20
33.81
36.50
38.78
35.32
40.39
43.84
50.93
54.42
58.16
66.72
SCOPE: Number
of programs >
$500K, 1986 $m
3.9
7.1
7.6
8.2
10.1
11.6
12.0
12.8
14.1
14.3
13.7
11.2
11.8
12.5
12.1
11.4
10.8
10.7
9.9
9.6
10.3
9.9
9.8
9.9
10.4
10.5
11.0
10.7
10.3
10.7
SALES
Total pharma.
sales,
1986 $m
1.99
4.81
5.41
6.36
7.52
8.74
10.27
11.80
12.73
14.77
16.49
18.14
19.35
20.24
20.19
20.69
20.91
22.17
22.04
23.02
24.39
23.39
22.62
21.76
22.57
24.64
23.94
25.45
29.70
31.36
YEAR
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
N
83
115
115
115
120
124
126
123
128
120
117
163
173
175
196
196
198
200
232
224
222
241
251
284
278
275
262
251
195
193
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Table (3): Determinants of patent output at the FIRM level.
Poisson Regression. Dependent variable = Total Firm PATENTS, 181 observations.
(1) (2) 1 (3) (4) (5)
Intercept 1.968** 0.189 -0.283* -0.617 0.121**
(0.101) (0.132) (0.147) (0.157) (0.159)
Ln(Total Firm Discovery) 0.084** 0. 154** 0.330** 0.288** 0.273**
(0.037) (0.040) (0.046) (0.047) (0.047)
Ln(Total Firm Stock of 0.286** 0.214** 0.330** 0.345** 0.216**
Discovery) (0.033) (0.049) (0.053) (0.053) (0.054)
SCOPE: No. classes firm is -0.053** 0.031** 0.055**
active (0.007) (0.015) (0.016)
SCOPE * SCOPE -0.004** -0.004**
(0.001) (0.001)
Total Firm Stock of own pats 0.0015**
(0.0002)
Firm dummies none Sig. Sig. Sig. Sig.
Time 0.155** 0.153** 0.156** 0.162** 0.118**
(0.007) (0.009) (0.009) (0.009) (0.011)
Time * Time -0.005** -0.006** -0.006** -0.006** -0.005**
(0.001) (0.001) (0.001) (0.002) (0.001)
Log-likelihood -2622.5 -1259.8 -1231.3 -1211.7 -1189.9
Standard errors in parentheses.
In(variable) is set=0O when variable=O, and an appropriately coded dummy variable is included in the regression.
** Significant at the 1% level.
* Significant at the 5 % level.
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Determinants of patent output at the research program level.
Poisson Regression. Dependent variable = PATENTS, 4879 observations.
Intercept
Ln(Discovery)
Ln(Stock of Discovery)
SCOPE: No. classes firm
is active
SCOPE * SCOPE
Ln(SIZE): Total disc.
spending by firm.
Stock own pats in this
class
News in patents in related
classes
News in discovery in
related classes
News in competitors'
patents in this class
News in competitors'
patents in related classes
Firm dummies
Class dummies
Time
Time * Time
Log-likelihood
(14)
-2.842**
(0.149)
0.048**
(0.010)
0.035**
(0.009)
0.112**
(0.016)
-0.007**
(0.001)
0.295**
(0.042)
0.035**
(0.001)
Sig.
Sig.
0.105**
(0.008)
-0.004**
(0.000)
-8269.1
(15)
-2.712**
(0.149)
0.041**
(0.010)
0.040**
(0.009)
0.106**
(0.015)
-0.006**
(0.001)
0.236**
(0.042)
0.032**
(0.001)
0.032**
(0.002)
Sig.
Sig.
0. 105**
(0.008)
-0.004**
(0.000)
-8192.0
(16)
-2.805**
(0.149)
0.051**
(0.010)
0.036**
(0.009)
0.111**
(0.016)
-0.006**
(0.001)
0.282**
(0.041)
0.033**
(0.001)
0.025*
(0.013)
Sig.
Sig.
0. 105**
(0.008)
-0.005**
(0.000)
-8259.1
(17)
-2.690**
(0.149)
0.042**
(0.010)
0.039**
(0.009)
0. 106**
(0.016)
-0.006**
(0.001)
0.233**
(0.042)
0.033**
(0.001)
0.032**
(0.002)
0.003
(0.012)
Sig.
Sig.
0.106**
(0.008)
-0.004**
(0.000)
-8183.9
(18)
-2.951**
(0.148)
0.038**
(0.009)
0.032**
(0.009)
0.110**
(0.016)
-0.006**
(0.001)
0.308**
(0.042)
0.031**
(0.001)
0.005**
(0.001)
0.003**
(0.001)
Sig.
Sig.
0.066**
(0.008)
-0.002**
(0.000)
-8105.1
(19)
-2.807**
(0.149)
0.030**
(0.010)
0.035**
(0.009)
0.105**
(0.016)
-0.006**
(0.001)
0.244**
(0.042)
0.032**
(0.001)
0.033**
(0.003)
0.007**
(0.001)
0.002**
(0.000)
Sig.
Sig.
0.069**
(0.010)
-0.003**
(0.001)
-8026.9
Standard errors in parentheses. In(variable) is set=0 when variable=O, and an appropriately coded dummy variable is included in
the regression. The omitted therapeutic class dummy is class60, systemic anti-infectives.
** Significant at the 1% level.
* Significant at the 5 % level.
i-------.
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Alternate Models
Dependent variable = PATENTS, 4879 observations.
Intercept
Ln(Discovery)
Ln(Stock of Discovery)
SCOPE: No. classes firm is
active
SCOPE * SCOPE
Ln(SIZE): Total disc.
spending by firm.
Stock own pats in this class
News in patents in related
classes
News in competitors'
patents in this class
News in competitors'
patents in related classes
Firm dummies
Class dummies
Time
Time * Time
overdispersion parameter
Log-likelihood
Poisson
(19)
-2.807**
(0.149)
0.030**
(0.010)
0.035**
(0.009)
0.105**
(0.016)
-0.006**
(0.001)
0.244**
(0.042)
0.032**
(0.001)
0.033**
(0.003)
0.007**
(0.001)
0.002**
(0.000)
Sig.
Sig.
0.069**
(0.010)
-0.003**
(0.001)
N/A
Negative
Binomial
(20)
-2.693**
(0.202)
0.061**
(0.015)
0.039**
(0.014)
0.104**
(0.023)
-0.006**
(0.001)
0.131*
(0.069)
0.052**
(0.002)
0.041**
(0.005)
0.012**
(0.001)
0.001
(0.001)
Sig.
Sig.
0.084**
(0.013)
-0.003**
(0.000)
0.518
(0.003)
-7131.61
Non-Linear
Least Squares
(21)
-2.267**
(0.313)
0.011
(0.021)
0.008
(0.022)
0.085*
(0.037)
-0.004**
(0.002)
0.298**
(0.085)
0.027**
(0.002)
0.022**
(0.005)
0.003
(0.002)
0.003**
(0.001)
Sig.
Sig.
0.020
(0.019)
-0.002**
(0.001)
N/A
R2=0.582
SER=2.240
Notes: see over.
Table (5a):
GMT
(22)
-2.113**
(0.234)
0.076**
(0.019)
0.053*
(0.018)
0.049
(0.028)
-0.004**
(0.001)
0.230**
(0.095)
0.057**
(0.026)
0.069**
(0.008)
0.01 1**
(0.001)
-0.002
(0.001)
Sig.
Sig.
0.071**
(0.016)
-0.002**
(0.001)
0.409
SER= .905
--------------------
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Table 5a Notes: Poisson model as in column (19) of Table (5).
Negative Binomial variance modelled as VAR(Y)=E[X](1 + aE[X])
Non-linear Least Squares: Y = exp(X/l) + E
GMT: weighted non-linear least squares, with weights derived from Poisson estimates of in
column (19): w=exp(XI)+i 2exp(XS)
Standard errors in parentheses. n(variable) is set=0 when variable=O, and an appropriately
coded dummy variable is included in the regression. The omitted therapeutic class dummy is
class60, systemic anti-infectives.
** Significant at the 1% level.
* Significant at the 5 % level.
----------------------
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Appendix One: Data Sources and Construction
The data set used in this study is based on detailed data on R&D inputs and outputs at the
research program level for ten ethical pharmaceutical manufacturers.
Inputs
Our data on inputs to the drug discovery process are taken from the internal records of
participating companies, and consist primarily of annual expenditures on exploratory research and
discovery by research program. Several issues arise in dealing with these data.
(a) Discovery vs. Development
The distinction between discovery and development is important. We define resources devoted
to discovery as all pre-clinical expenditures within a therapeutic class, and development as all
expenses incurred after a compound has been identified as a development candidate. Where
exploratory research was attributable to a particular research program, this is included in the
discovery category. Non-program exploratory research was included in the overhead allocation for
each research program. Clinical grants are included in the figures for development, and grants to
external researchers for exploratory research are included in the total for discovery.
In some cases, the companies supplied us with data already broken down by discovery vs
development by research program. In others, we had to classify budget line items for
projects/programs into the appropriate category. This was done based on the description of each item
in the original sources, and the location of items within the structure of the company's reporting
procedure.
(b) Overhead
In order to maintain as much consistency in the data collection process as possible, we tried to
ensure that these figures include appropriate overhead charges directly related to discovery activities,
such as computing, R&D administration and finance etc., but exclude charges relating to allocation of
central office overhead etc. The overhead also includes some expenditures on discipline-based
exploratory research such as "molecular biology" which appeared not to be oriented towards specific
therapies. Overhead was allocated across therapeutic classes according to their fraction of total
spending.
(c) Licensing
We treat up-front, lump-sum payments in respect of in-licensing of compounds, or
participation in joint programs with other pharmaceutical companies, universities or research
institutes, as expenditure on discovery. Royalty fees and contingent payments are excluded.
Outputs
In this paper we focus on patent grants as our measure of research output. We count patents
by year of application. Our interest here is on determinants of technical success, defined in terms of
""rBsp---""--smurrr·I---·------·^-- -- ----- ------ 
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producing new potentially important compounds, rather than on the ultimate commercial success or
failure of new drugs. Since Patent Examiners award grants based on slowly changing objective
criteria of novelty, non-obviousness, and potential industrial application, we believe that patent grants
are an appropriate basis for measuring research output in this industry. Pharmaceutical companies
patent prolifically, and patents are, of course, a rather noisy measure of research success, in part
because the significance of individual patents varies widely. We partially control for this by counting
only "important" patents, where we define "importance" by the fact that the patent was granted in two
of the three major markets: the USA, Japan, and the European Community.
These data were provided by Derwent Publications Inc, who we asked to use their proprietary
classification and search software to produce counts of "important" patents to us broken down by
therapeutic class for 29 US, European, and Japanese pharmaceutical manufacturers for the 26 years
preceding 1990. These firms were chosen to include the ten firms that have given us data together
with 19 other firms chosen on the basis of their absolute R&D expenditures, R&D intensity, and
national "home base" to try to get a representative, rather than exhaustive, assessment of world-wide
patenting activity. These 19 firms have been consistently in the top 40 world wide pharmaceutical
firms in terms of R&D dollars and sales.
Note that many of these patents will be "defensive" patents in that firms may patent
compounds they do not intend to develop in the short term but that may have competitive value in the
longer term. Alternative measures of "importance" include citation weighting and more detailed
international filing data - "very" important patents are usually filed in nearly every major potential
market. We hope to explore these alternative measures in later work.
Classification
Classification of inputs and outputs by therapeutic class is important because this drives our
measure of spillovers. There are essentially two choices: to define programs by physiological
mechanisms, e.g. "prostaglandin metabolism", or by "indications" or disease states, e.g. "arthritis".
We have chosen to classify on the basis of indication, largely because this corresponds well to the
internal divisions used by the companies in our sample (which is conceptually correct), but also
because classification by mechanism is much more difficult (a practical concern.) In further work we
intend to repeat the analysis using a "cut" by mechanism. We classified both inputs and outputs
according to a scheme which closely follows the IMS Worldwide classes. This scheme contains two
tiers of aggregation: a detailed "research program" level, and a more aggregated "therapeutic class"
level which groups related programs. For example, the therapeutic class "CARDIOVASCULAR"
includes the research programs "ANTI- HYPERTENSIVES", "CARDIOTONICS",
"ANTITHROMBOLYTICS", "DIURETICS" etc.
There are some problems with this procedure. Firstly, some projects and compounds are
simply very difficult to classify. A particular drug may be indicated for several quite distinct
therapies: consider serotonin, which has quite different physiological actions on either side of the
blood-brain barrier. As a neurotransmitter it is believed to play important roles in mediating motor
functions. As a systemic hormone it has a variety of effects on smooth muscle, for example it
functions as a vasoconstrictor. Some companies report expenditures in areas which are very difficult
to assign to particular therapeutic classes: a company doing research using rDNA technology might
charge expenditure to an accounting category listed as "Gene Therapy/Molecular Biology" which is
actually specific research performed on e.g. cystic fibrosis, but we have no idea about which diseases
the research is directed towards treating, and are forced to include these expenditures in "overhead".
_Ulj···e__llll________
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Secondly, our two-tier classification scheme may not catch all important relationships between
different therapeutic areas. We believe that we are undercounting, rather than overcounting in this
respect, so that the importance of spillovers will be underestimated rather than overestimated.
Thirdly, where firms supplied us with "pre-digested" data, they may have used substantively different
conventions in classifying projects. One firm may subsume antiviral research under a wider class of
anti-infectives, while another may report antivirals separately. Not surprisingly there are major
changes within companies in internal divisional structures, reporting formats, and so forth, which may
also introduce classification errors. After working very carefully with these data, we recognize the
potential for serious miss-assignment of outputs to inputs, but we believe that such errors that remain
are not serious. The use of patents as the output measure should reduce vulnerability to this problem,
since we observe relatively large numbers, and a few miss- classifications are unlikely to seriously
affect our results. When we move to INDs and NDAs as our output measures, the much more
sparsely distributed data are likely increase our vulnerability.
Matching
Data series on inputs and outputs for each firm were matched at the research program level.
This procedure appears to successfully match outputs and inputs unambiguously for the great majority
of programs. In a very few cases, however, we ended up with research programs where patents,
INDs or NDAs were filed, but where there were no recorded expenditures. Of these the majority
were obviously coding errors or reflected dilemmas previously encountered in the classification
process, and appropriate corrections were made. In other cases, it was clear that these reflected
"spillovers" -- research done ostensibly in, for example, hypertension, may generate knowledge about
the autonomic nervous system which prompts patenting of compounds may be useful in treating
secretory disorders (e.g. ulcers.) In such cases we set "own" inputs for the program equal to zero,
and included these observations in the data base.
Deflation
Since our data sources span many years, it is important to base the analysis on constant dollar
expenditures. We used the R&D price deflator constructed by Edwin Mansfield (-1987) for his Oil
and Chemicals industry grouping. This index is based on wage rates for R&D employees, and a price
index for equipment and instrumentation purchases, and though its movement is quite different from
the CPI or the GNP deflator, it varies much less across industries, leading us to believe that it may be
a reasonable approximation to the "correct" index for pharmaceuticals. Mansfield's index exists only
for 1969-1983, we extended it backwards to 1966 and forwards to 1990 using movement in the CPI.
The periods 1966-1969 and 1983-1990 saw relatively little price inflation, so this approximation is
unlikely to be serious problem. In a later paper we intend to exploit the information that some
companies were able to give us on R&D inputs in units of labor hours to construct an index
specifically for research costs in the pharmaceutical industry.
I------ ----- -- -I-i---------
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Definition of Variables Used in the Regression Analysis
Observations are identified by (encoded) FIRM, CLASS, and YEAR.
Construction of stock variables
Annual flows of discovery and expenditures were capitalized following the procedure
described by Hall et al. (The R&D Masterfile: Documentation, NBER Technical WP #72). In brief,
we first assume a depreciation rate for "knowledge capital" , 6, here equal to 20%. (This is consistent
with previous studies, and as argued above is not going to be very important in terms of it's impact
on the regression results since no matter what number we chose, if the flow series is reasonably
smooth we would still find it difficult to identify 6 separately from the estimated coefficient on the
stock variable.) We then calculate a starting stock for each class within firm based on the first
observation on the annual flow: assuming that real expenditures have been growing since minus
infinity at a rate g, we divide the first observed year's flow by 6+g. Each year, the end-of-year is set
equal to the beginning-of-year stock net of depreciation, plus that year's flow. For the cases where the
annual flow was missing "within" a series of observations, we set it equal to zero. In almost all
instances, these missing values occur after the expenditure flows have been declining towards zero:
we are reasonably that these are "real" zeros and not missing data which should be interpolated. We
used the same procedure to accumulate "stocks" of patents, based on the flow variables described
above.
DISCOVERY Expenditures by this firm in this research area, relating
primarily to production of new compounds, by year, in
millions of constant 1986 dollars.
own PATENTS Important patents granted to this firm in this research area,
by year, from the Derwent database. Note that throughout
the analysis we count patents by year of application.
own PATENTS in related Important patents granted to this firm in the related
programs therapeutic class, net of the patents granted in this research
area.
PATENTS in this program area by Important patents granted this year in this research area to
other firms: 29 other major multinational firms.
PATENTS in related programs by Important patents granted in related therapeutic classes this
other firms: year to 29 other major pharmaceutical firms.
SCOPE The number of research areas in which this firm has spent
at least $0.5m dollars on discovery this year.
SIZE Total research expenditure by this firm in this year across
all therapeutic classes.
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Appendix Two: Therapeutic Class Definition
Class 10 Alimentary Tract and Metabolism
Class 20 Blood and Blood Forming Organs
Class 30 The Cardiovascular System
Class 40 Dermatologicals
Class 50 Genito-Urinary System and Sex Hormones
Class 60 General anti-infectives, systemic.
Class 90 Cytostatics
Class 100 Musculo-Skeletal System
Class 110 Central Nervous System
Class 120 Parasitology
Class 130 Respiratory System
Class 140 Sensory Organs
Class 150 Allergens and Immunomodulators
Class 160 All other therapeutics.
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